StockData
Recursion Pharmaceuticals, Inc. logo

Recursion Pharmaceuticals, Inc. (RXRX) stock

RXRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/302% below fair value
$2.90−0.28 (-8.79%)

Close on Nov 16, 2026Market cap $1.56BP/E –Yield –

How the market prices Recursion Pharmaceuticals

Each ratio against its own distribution since 2021, from month-end prices and the figures reported at the time

Recursion Pharmaceuticals trades at 28.4× its earnings, against a median of 41.2× since 2021 — cheaper than 91% of the months in between.

The shaded bar covers the 5th to 95th percentile of month-end values since 2021, the darker part the 25th to 75th, the line the median and the dot today. The figure on the right is the percentile today sits at.

Price to sales since 2021

Median 41.2×, today 28.4×

What Recursion Pharmaceuticals keeps of every dollar

Trailing twelve months, from revenue down to net income. Grey columns are what comes out.

Margins against the industry

Gross margin3.49%vs 52.9%
Operating margin-991.7%vs -42.9%
EBITDA margin-848.9%vs -30.2%
Pretax margin-954.3%vs -13.0%
Net margin-945.9%vs -39.9%
Free cash flow margin-642.2%vs -9.41%

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

What it earns on the capital it uses

Trailing twelve months over average capital

Return on equity-56.6%vs -53.5%
Return on assets-41.3%vs -40.7%
Return on invested capital-108.6%vs -33.0%
Return on capital employed-49.8%vs -38.7%

How hard the assets work

Revenue per dollar of assets0.04vs 0.39
Revenue per employee$1.10Mvs $405.05K
Profit per employee-$10.38Mvs -$704.12K

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

What it owes and what covers it

Latest balance sheet, against twelve months of cash generation

Cash and short-term investments exceed every borrowing by $531.49M. That is 51.9% of the $1.02B it would cost to buy the business outright.

Total debt$14.20M
Cash and short-term investments$545.68M
EBITDA, trailing twelve months-$465.65M
Free cash flow, trailing twelve months-$352.27M

Leverage and liquidity

Debt to equity0.02vs 0.50
Current ratio5.03vs 3.30
Quick ratio4.55vs 2.39

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

Scores and rules of thumb

Academic scores computed from the latest two fiscal years. They are screens, not verdicts.

Altman Z-Score

Five ratios that together predicted bankruptcy within two years.

-0.51
DistressGrey zoneSafe

Piotroski F-Score

Nine yes-or-no tests of profit, leverage and efficiency against last year.

3 of 9 tests passed

What comes back to shareholders

Trailing twelve months against the market value at the latest close

Earnings yield-33.4%vs -22.5%
Free cash flow yield-22.7%vs -9.27%
Buyback yield-24.9%vs -0.65%
Shareholder yield-24.9%vs 0.00%

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

How the shares have traded

Total return includes reinvested dividends, to the close on Nov 16, 2026

$2.7752-week low52-week high$5.24
$2.90200-day20-day50-day

The close sits 5% of the way up the 52-week range, 44.6% below the high.

Relative strength index, 14 days

How much of the recent move has been upward. Extremes are where traders look for a turn.

36
OversoldNeutralOverbought

Total return against the S&P 500

The axis is compressed: each step is ten times the one before, so a month and a decade fit on the same line.

RXRXS&P 500
PeriodRXRXS&P 500DifferenceRXRX per yearS&P 500 per year
1 month-16.2%-3.1%−13.1 pts
3 months-8.1%-4.5%−3.6 pts
Year to date-29.0%+9.4%−38.3 pts
1 year-29.8%+11.3%−41.1 pts
3 years-56.4%+70.4%−126.9 pts-24.2%+19.4%
5 years-85.5%+68.6%−154.1 pts-32.0%+11.0%

How much it moves

Volatility, 1 year75.0%vs 80.4%
Volume against its 90-day average0.92vs 0.86

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

Who is betting against it

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

142M RXRX shares were sold short on Oct 30, 2026, down 12.1% from the previous report, or 28.15% of the shares available to trade. At recent volumes it would take 6.1 days to buy them back. Over the last 20 sessions, 50.3% of the volume reported to FINRA was short selling.

Shares sold shortDays to cover
Short interest as a share of the float28.2%vs 8.91%
Short interest as a share of all shares26.6%vs 6.30%
Days of volume to buy it back6.10vs 5.16

The grey tick and the second figure are the median of companies in the same industry group; green means this company is on the better side of it.

The last twelve reports

Settlement dateShares shortChangeAvg. daily volumeDays to cover
Oct 30, 2026142,265,985-12.1%23,330,4716.1
Oct 15, 2026161,926,247+2.5%36,463,2134.4
Sep 30, 2026157,938,412-11.6%25,774,8406.1
Sep 15, 2026178,724,433-0.2%14,224,30012.6
Aug 31, 2026179,145,796+0.7%16,898,23610.6
Aug 14, 2026177,923,359-1.6%13,306,55213.4
Jul 31, 2026180,771,459+0.0%19,411,8659.3
Jul 15, 2026180,760,541+4.9%26,882,1896.7
Jun 30, 2026172,302,180-6.4%20,547,1138.4
Jun 15, 2026184,017,785+12.0%22,006,6648.4
May 29, 2026164,340,230-10.9%20,501,1788.0
May 15, 2026184,440,829+7.7%13,889,49813.3

Every measure, in full

85 figures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings
Feb 24, 2027 (estimated, before the open)
Last ex-dividend date
No dividends
Fundamentals through
Jun 30, 2026
Share price as of
Nov 16, 2026

Valuation ratiosIndustry

Market Cap
$1.56B
$261.21M
Enterprise Value
$1.02B
$135.05M
PS Ratio
28.35
3.76
PB Ratio
1.70
2.00
P/TBV Ratio
3.30
2.22

Enterprise valuationIndustry

EV / Sales
18.66
2.44

Share statisticsIndustry

Shares Change (YoY)
41.1%
10.9%
Shares Change (QoQ)
0.66%
0.57%
Float
505M
49M
Shares Held by Insiders
5.61%
11.2%
Shares Held by Institutions
67.6%
56.2%

Short sellingIndustry

Short Interest
142M
–
Short Interest Change
-12.1%
-0.81%
Short % of Float
28.2%
8.91%
Short % of Shares Outstanding
26.6%
6.30%
Days to Cover
6.10
5.16

Stock price statisticsIndustry

52-Week High
$5.24
–
52-Week Low
$2.77
–
20-Day Moving Average
$3.69
–
50-Day Moving Average
$3.77
–
200-Day Moving Average
$3.47
–
Average True Range (14)
$0.33
–
Price Change (1 Week)
-23.7%
-7.55%
Price Change (1 Month)
-16.2%
-4.88%
Price Change (3 Months)
-5.99%
-24.2%
Price Change (6 Months)
0.52%
-21.7%
Price Change (YTD)
-29.0%
-26.2%
Price Change (1 Year)
-32.9%
-22.5%
Price Change (3 Years)
-58.8%
-31.7%
Price Change (5 Years)
-85.0%
-78.2%
Average Volume (10 Days)
20M
–
Average Volume (20 Days)
20M
–
Average Volume (90 Days)
22M
–
Relative Volume
0.92
0.86
Relative Strength Index (14)
35.7
40.8
Volatility (1 Year)
75.0%
80.4%

MarginsIndustry

Gross Margin
3.49%
52.9%
Operating Margin
-991.7%
-42.9%
Pretax Margin
-954.3%
-13.0%
Profit Margin
-945.9%
-39.9%
EBITDA Margin
-848.9%
-30.2%
FCF Margin
-642.2%
-9.41%

Returns on capitalIndustry

Return on Equity (ROE)
-56.6%
-53.5%
Return on Assets (ROA)
-41.3%
-40.7%
Return on Invested Capital (ROIC)
-108.6%
-33.0%
Return on Capital Employed (ROCE)
-49.8%
-38.7%

Financial positionIndustry

Current Ratio
5.03
3.30
Quick Ratio
4.55
2.39
Debt / Equity
0.02
0.50
Interest Coverage
-367.32
-6.20

GrowthIndustry

Revenue Growth (YoY)
-15.1%
5.71%
Revenue Growth (3Y CAGR)
23.3%
2.25%
Revenue Growth (5Y CAGR)
79.9%
6.41%

EfficiencyIndustry

Asset Turnover
0.04
0.39
Revenue Per Employee
$1.10M
$405.05K
Profits Per Employee
-$10.38M
-$704.12K
Employee Count
50
75

Income statement (TTM)Industry

Revenue
$54.86M
$58.79M
Gross Profit
$1.91M
$103.58M
Operating Income
-$544.01M
-$21.49M
Pretax Income
-$523.47M
-$14.83M
Net Income
-$518.88M
-$22.47M
EBITDA
-$465.65M
-$17.14M
EPS (Diluted)
-$1.04
-$0.83

Balance sheetIndustry

Total Debt
$14.20M
$116.91M
Net Cash (Debt)
$531.49M
$15.35M
Net Cash Per Share
$0.99
$0.71
Equity (Book Value)
$915.00M
$49.84M
Book Value Per Share
$1.71
$1.45
Tangible Book Value
$471.77M
$23.91M
Working Capital
$483.58M
$74.41M

Cash flow (TTM)Industry

Operating Cash Flow
-$350.48M
-$12.17M
Capital Expenditures
-$1.79M
-$1.03M
Free Cash Flow
-$352.27M
-$20.28M
FCF Per Share
-$0.66
-$0.42

Dividends and yieldsIndustry

Earnings Yield
-33.4%
-22.5%
FCF Yield
-22.7%
-9.27%
Buyback Yield
-24.9%
-0.65%
Shareholder Yield
-24.9%
0.00%

Taxes and interestIndustry

Interest Expense
$1.48M
$3.07M
Income Tax
-$4.58M
$80.43K

Scores and fair valueIndustry

Altman Z-Score
-0.51
0.22
Piotroski F-Score
3
4

Ratios use trailing-twelve-month results and the latest balance sheet. How we calculate.

See a number that looks wrong?